Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; a license agreement with City of Hope; and a licensing and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-621-8097
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.28 million
Profitability
Miscellaneous
Employees44
OptionableOptionable
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.11. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analysts' expectations of $1.67 million. Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
9 analysts have issued 1 year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $14.50 to $30.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $21.3125 in the next year. This suggests a possible upside of 97.9% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.
What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
Headlines about DRNA stock have trended neutral recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,979,289 shares, an increase of 75.9% from the December 14th total of 3,399,119 shares. Based on an average daily volume of 929,548 shares, the days-to-cover ratio is presently 6.4 days. Approximately 13.2% of the shares of the company are short sold. View Dicerna Pharmaceuticals' Current Options Chain.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN) and Innoviva (INVA).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 49)
- Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)
- Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 65)
- Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
- Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71)
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $10.77.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $675.62 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
What is Dicerna Pharmaceuticals' official website?
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
